AbbVie has filed three material events in rapid succession (April 29, May 12, June 22, 2026) related to Botox, Juvéderm, and the Allē loyalty platform—a pattern that typically precedes pricing adjustments, rebate restructuring, or competitive response to market share loss. Material event filings are required when a company believes an event is material to investors; three filings in eight weeks suggests either internal reorganization or external competitive pressure forcing margin defense.